---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-026761"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:05:08.550402+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# VYNE extends Oral BETi option to April 30, 2023; regains Nasdaq minimum bid price compliance

## Summary
- Extended option term for Oral BETi Compounds to April 30, 2023; paid Tay $250k non-refundable fee.
- Fee will be deducted from $4.0M upfront if option exercised.
- Received Nasdaq notice on Feb 28, 2023 that bid price ≥$1.00 for 10 consecutive business days through Feb 27, 2023.
- Regained compliance with Nasdaq Rule 5550(a)(2).

## SEC filing metadata
- accession: 0001104659-23-026761
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465923026761/0001104659-23-026761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465923026761/tm237985d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-026761
- JSON: https://secwatch.observer/filing/0001104659-23-026761.json
- Plain text: https://secwatch.observer/filing/0001104659-23-026761.txt

## Key facts
- Material Agreements
  VYNE Therapeutics Inc. amended Letter Agreement with Tay Therapeutics Limited valued at $250,000 (effective 2023-02-27).
  - Action: amendment
  - Agreement: license
  - Counterparty: Tay Therapeutics Limited
  - Value: $250,000
  - Effective: 2023-02-27
  source text: the parties entered into a Letter Agreement on February 27, 2023 (the “Letter Agreement”) to extend the Option Term to April 30, 2023. Pursuant to the terms of the Letter Agreement, VYNE has agreed to pay Tay a non-refundable fee in the amount of $250,000 to extend the Option Term.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465923026761/0001104659-23-026761-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.